Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.50 |
| ▸ | TTK | P33981 | 1/20 | 0.46 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15651827 | 0.77 | TTK (0.49) | GSK3BTTKKIF11 | |
| SCHEMBL29957557 | 0.77 | TTK (0.49) | GSK3BTTKKIF11 | |
| SCHEMBL15652140 | 0.74 | TTK (0.52) | GSK3BTTKKIF11 | |
| SCHEMBL15652215 | 0.73 | TTK (0.46) | GSK3BTTKMAPK1KIF11 | |
| SCHEMBL13727221 | 0.73 | PDPK1 (0.55) | TTKKIF11 | |
| SCHEMBL13996487 | 0.73 | UTS2R (0.50) | TTK | |
| SCHEMBL3538242 | 0.73 | TTK (0.54) | TTKKIF11 | |
| SCHEMBL17094915 | 0.71 | TTK (0.44) | GSK3BTTKDYRK1AKIF11 | |
| SCHEMBL29952255 | 0.71 | TTK (0.52) | GSK3BTTKMAP2K4KIF11 | |
| SCHEMBL578196 | 0.71 | TTK (0.52) | GSK3BTTKKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | GSK3B 174/4885TTK 101/4885MAP2K4 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.